Benzo[D]Isoxazole

Benzo[D]Isoxazole

SCHEMBL5773958

CS(=O)(=O)Cl.c1ccc2oncc2c1

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.34
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34
LMNA P02545 3/20 0.34
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CA2 P00918 4/20 0.33
TRPM5 Q9NZQ8 1/20 0.31
PTGS2 P35354 1/20 0.31
CA12 O43570 3/20 0.31
CA1 P00915 3/20 0.31
CA9 Q16790 3/20 0.31
MAOB P27338 2/20 0.31
CA3 P07451 2/20 0.31
CA4 P22748 2/20 0.31
CA6 P23280 2/20 0.31
CA5A P35218 2/20 0.31
CA7 P43166 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzo[D]Isoxazole SCHEMBL5773956 0.91 TDP1 (0.35) TDP1ALDH1A1HSD17B10LMNANPC1
Benzo[D]Isoxazole SCHEMBL5697378 0.89 NPC1 (0.40) TDP1ALDH1A1LMNAGAAALOX15
Benzo[D]Isoxazole SCHEMBL5697384 0.87 NPC1 (0.39) TDP1ALDH1A1LMNAGAAALOX15
Benzo[D]Isoxazole SCHEMBL5697385 0.87 CYP3A4 (0.36) TDP1ALDH1A1LMNAGAAALOX15
Benzo[D]Isoxazole SCHEMBL5918862 0.87 NPC1 (0.39) TDP1ALDH1A1LMNAGAAALOX15
Benzo[D]Isoxazole SCHEMBL6298798 0.87 RAB9A (0.39) TDP1ALDH1A1LMNAGAAALOX15
Benzo[D]Isoxazole SCHEMBL1355530 0.84
Benzo[D]Isoxazole SCHEMBL8438 0.84
Benzo[D]Isoxazole SCHEMBL29366929 0.84
Benzo[D]Isoxazole SCHEMBL27515218 0.82 CA12 (0.35) TDP1LMNANPC1RAB9ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936720-B2 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-08-30 US claimed
US-20060287535-A1 Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide WOCKHARDT LIMITED 2006-12-21 US disclosed
US-20060084814-A1 Process for the preparation of zonisamide GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-04-20 US disclosed
EP-1472236-A4 METHOD FOR PREPARING BENZISOXAZOLE METHANE SULFONYL CHLORIDE AND ITS AMIDATION TO FORM ZONISAMIDE TEVA PHARMA (IL) 2006-04-19 EP disclosed
US-20060069267-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms NIDAM TAMAR 2006-03-30 US disclosed
US-20060063936-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms NIDAM TAMAR 2006-03-23 US disclosed
US-7015330-B2 Sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-03-21 US disclosed
US-6936720-B2 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-08-30 US disclosed
US-6936720-B2 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-08-30 US disclosed
CN-1636002-A Method for preparing benzisoxazole methylsulfonyl chloride and amidating it to form zonisamide TEVA PHARMA (IL) 2005-07-06 CN disclosed
US-20040138471-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms MENDELOVICI MARIOARA (IL) 2004-07-15 US disclosed
US-20040138472-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms MENDELOVICI MARIOARA 2004-07-15 US disclosed
EP-1430037-A1 ZONISAMIDE INTERMEDIATE AND SYNTHESIS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-06-23 EP disclosed
WO-2004020419-A1 NOVEL SULFONATION METHOD FOR ZONISAMIDE INTERMEDIATE IN ZONISAMIDE SYNTHESIS AND THEIR NOVEL CRYSTAL FORMS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-03-11 WO disclosed
US-20040014983-A1 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide TEVA PHARMACEUTICALS USA INC. 2004-01-22 US disclosed
US-20040014983-A1 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide TEVA PHARMACEUTICALS USA INC. 2004-01-22 US disclosed
WO-2003072552-A1 METHOD FOR PREPARING BENZISOXAZOLE METHANE SULFONYL CHLORIDE AND ITS AMIDATION TO FORM ZONISAMIDE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-09-04 WO disclosed
US-20030144527-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms TEVA PHARMACEUTICALS USA, INC. 2003-07-31 US disclosed
US-20030114682-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-06-19 US disclosed
WO-2003020708-A1 ZONISAMIDE INTERMEDIATE AND SYNTHESIS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138471-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms CA3, ARSA, CBS TDP1 4808/4885ALDH1A1 1574/4885HSD17B10 934/4885
US-20040138472-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms CA3, ARSA, CBS TDP1 4808/4885ALDH1A1 1574/4885HSD17B10 934/4885
US-20060084814-A1 Process for the preparation of zonisamide CYP3A43, CYP3A4, CYP3A5 TDP1 4729/4885ALDH1A1 1122/4885HSD17B10 797/4885
US-20030114682-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms CA3, ARSA, CBS TDP1 4808/4885ALDH1A1 1574/4885HSD17B10 934/4885
US-20060069267-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms CA3, ARSA, CBS TDP1 4808/4885ALDH1A1 1574/4885HSD17B10 934/4885
US-20030144527-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms ARSA, BCHE, CA3 TDP1 4780/4885ALDH1A1 994/4885HSD17B10 694/4885
US-20060287535-A1 Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide GABRE, CA3, GABRA1 TDP1 4582/4885ALDH1A1 2084/4885HSD17B10 2175/4885
US-20040014983-A1 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide GABRA2, GABRA5, GABRA4 TDP1 4860/4885ALDH1A1 3916/4885HSD17B10 4090/4885
US-20060063936-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms CA3, ARSA, CBS TDP1 4808/4885ALDH1A1 1574/4885HSD17B10 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.